Boyang Bian

5PUBLICATIONS
23CO-AUTHORS
Medical infection agents (incl. prions)Neurology and neuromuscular diseasesMedical biochemistry - proteins and peptides (incl. medical proteomics)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 18, 2026
Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies.

|Jun 21, 2026
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.

|Feb 18, 2026
Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.

Ahmed Z Obeidat, Michelle Betz, Rebecca Straus Farber

|Jun 16, 2025
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis.

Sophia Woodson, Edward J Gettings, Chu-Yueh Guo

|May 29, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with Natalizumab.

Karen Blitz-Shabbir, Aimee M Banks, Hina Garg

Pageof 1

Frequent Collaborators

4 joint publications

Jason P Mendoza

3 joint publications

Sai L Shankar

3 joint publications

James B Lewin

2 joint publications

Ahmed Z Obeidat